These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11992888)

  • 1. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Camras CB
    Am J Ophthalmol; 2002 May; 133(5):732; author reply 732-3. PubMed ID: 11992888
    [No Abstract]   [Full Text] [Related]  

  • 2. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
    Li N; Chen XM; Zhou Y; Wei ML; Yao X
    Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
    Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
    Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the fixed combination of bimatoprost/timolol really produce a better benefit/risk balance than the fixed combination of latanoprost/timolol?
    Soto J; Diaz S
    Eur J Ophthalmol; 2010; 20(1):246-7; author reply 247-8. PubMed ID: 20047180
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy.
    Kashiwagi K
    Jpn J Ophthalmol; 2012 Jul; 56(4):339-45. PubMed ID: 22581454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.
    Eisenberg DL; Toris CB; Camras CB
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S105-15. PubMed ID: 12204706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
    Noecker RS; Dirks MS; Choplin N;
    Am J Ophthalmol; 2004 Jan; 137(1):210-1; author reply 211-2. PubMed ID: 14700685
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma.
    Parmaksiz S; Yüksel N; Karabas VL; Ozkan B; Demirci G; Caglar Y
    Eur J Ophthalmol; 2006; 16(1):73-80. PubMed ID: 16496249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment on Efficacy and tolerability of prostaglandin analogs.
    Eisenberg D
    J Glaucoma; 2009 Aug; 18(6):498; author reply 498-9. PubMed ID: 19593206
    [No Abstract]   [Full Text] [Related]  

  • 12. A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy.
    Fain JM; Kotak S; Mardekian J; Bacharach J; Edward DP; Rauchman S; Brevetti T; Fox JL; Lovelace C
    BMC Ophthalmol; 2011 Jun; 11():13. PubMed ID: 21668980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
    Parrish RK; Palmberg P; Sheu WP;
    Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study.
    Bernstein P
    Am J Ophthalmol; 2004 Feb; 137(2):387-8; author reply 388-9. PubMed ID: 14962451
    [No Abstract]   [Full Text] [Related]  

  • 16. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects.
    Halpern MT; Covert DW; Robin AL
    Trans Am Ophthalmol Soc; 2002; 100():109-17; discussion 117-8. PubMed ID: 12545683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment carryover impacts on effectiveness of intraocular pressure lowering agents, estimated by a discrete event simulation model.
    Denis P; Le Pen C; Umuhire D; Berdeaux G
    Eur J Ophthalmol; 2008; 18(1):44-51. PubMed ID: 18203084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
    Chiseliţă D; Antohi I; Medvichi R; Danielescu C
    Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, prospective study of bimatoprost 0.01% or travoprost/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressure.
    Nixon DR
    J Ocul Pharmacol Ther; 2013 Dec; 29(10):876-81. PubMed ID: 24070367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.